High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

DISEASE CHARACTERISTICS:

• Histologically confirmed advanced carcinomas of the following types:
• Breast carcinoma that is ineligible for or patient has refused participation in a higher priority protocol in the following categories:
• Stage II disease with at least 10 involved lymph nodes and no evidence of disease (NED) following surgery
• Stage III disease rendered surgically NED with or without radiotherapy
• Stage IV disease following partial response (PR) or complete response (CR) to surgery, chemotherapy, or radiotherapy
• Prior high dose chemotherapy allowed at discretion of investigator
• No chemoresistant disease rendered surgically NED
• Locoregionally recurrent disease within 2 years of breast conservation with or without chemotherapy
• Stage III/IV ovarian cancer
• PR/CR following debulking surgery and/or chemotherapy
• Ineligible for or refused participation in higher priority protocols
• Primary soft tissue sarcoma with high-grade disease greater than 10 cm or that is metastatic
• Rendered surgically NED or achieved PR/CR on any chemotherapeutic or immunotherapeutic regimen
• Ineligible for or refused participation in higher priority protocols
• Malignant melanoma in the following categories:
• Ulcerative primary tumor with any number of completely resected metastatic lymph nodes
• Stage II disease with more than 4 involved nodes rendered NED
• Stage III disease rendered surgically NED or achieved PR/CR on any chemotherapeutic or immunotherapeutic regimen
• Osteosarcoma that is ineligible for or refused participation in higher priority protocols
• Resected primary with less than 50% tumor necrosis on pathologic review
• Metastatic disease rendered surgically NED or PR/CR on any chemotherapeutic, radiotherapeutic, or immunotherapeutic regimen
• The following diseases rendered surgically NED or that achieved PR/CR on any chemotherapeutic, radiotherapeutic, or immunotherapeutic regimen also eligible:
• Small cell bone carcinoma
• Metastatic Ewing's sarcoma
• Metastatic gastrointestinal malignancy
• Recurrent Wilms' tumor
• No CNS metastases
• No current histologically confirmed bone marrow metastases
• Prior bone metastases with resolution at time of entry permitted

PATIENT CHARACTERISTICS:

Age:

• Physiologic 18 to 55

Performance status:

• Karnofsky 80%-100%

Hematopoietic:

• Absolute neutrophil count greater than 1,500/mm3
• Platelet count greater than 120,000/mm3
• Hemoglobin greater than 10 g/dL

Hepatic:

• Bilirubin less than 1.5 mg/dL
• AST/ALT less than 3 times normal

Renal:

• Creatinine less than 1.4 mg/dL
• Creatinine clearance at least 70 mL/min
• No history of hemorrhagic cystitis

Cardiovascular:

• Ejection fraction at least 55% by MUGA
• No significant cardiac disease

Pulmonary:

• FEV1 greater than 2 L
• pO2 (room air) greater than 70 mm Hg
• pCO2 (room air) less than 42 mm Hg
• DLCO greater than 60% of predicted

Other:

• No potentially disabling psychosocial history
• No organic or functional CNS dysfunction or other medical problem that would present party at undue risk
• HIV negative
• Hepatitis B surface antigen negative
• No hearing loss greater than 40 decibels
• No contraindication to the following procedures:
• Collection by apheresis of up to 16 x 10 to the 8th mononuclear cells mobilized by G-CSF
• Collection of autologous bone marrow, if needed
• No second malignancy except:
• Nonmelanomatous skin cancer
• Carcinoma in situ of the cervix
• Not pregnant or nursing
• Adequate contraception required of fertile patients

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics
• At least 4 weeks since prior immunotherapy

Chemotherapy:

• See Disease Characteristics
• No more than 3 prior chemotherapy regimens (excluding adjuvant therapy)
• No more than 200 mg per square meter of prior cisplatin
• No more than 800 mg per square meter of prior carboplatin
• No prior exposure to greater than 1,000 mg per square meter of "24-hour paclitaxel equivalents" (using a 1:1.3 ratio between paclitaxel doses given by 24-hour infusion and by 3-hour infusion)
• At least 4 weeks since prior chemotherapy

Endocrine therapy:

• Not specified

Radiotherapy:

• No prior radiotherapy to more than 20% of bone marrow
• At least 4 weeks since prior radiotherapy

Surgery:

• See Disease Characteristics